Sedor Pharmaceuticals Files NDA for CE-Fosphenytoin for Status Epilepticus

Sedor Pharmaceuticals Files NDA for CE-Fosphenytoin for Status Epilepticus Potential significant advance in the treatment of life-threatening condition May 30, 2018, 10:00 AM Eastern Standard Time PAOLI, Pa.,–(BUSINESS WIRE)— Sedor Pharmaceuticals, LLC (Sedor) announced that it has filed with the US FDA an NDA for the approval of Sedor’s lead program, IM/IV Captisol-Enabled™ (CE) Fosphenytoin […]